SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.

摘要: Euglycemic diabetic ketoacidosis (EuDKA) secondary to Sodium-glucose co-transporter-2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2D) is a rare but increasingly reported phenomenon. Not much known about the burden of EuDKA patients on SGLT2i or associated factors. This retrospective cohort study tries delineate differences factors with development as compared hyperglycemic DKA. We conducted multicentre, across three tertiary care centers under Weill Cornell affiliated-Hamad Medical Corporation, Qatar. The comprised T2D who developed DKA between January 2015 December 2020. subjects hyperglycaemic (hDKA) were analyzed. A total 9940 during 2015-2020, out which 43 (0.43%). 25 EuKDA, whereas 18 had hDKA. point prevalence our was 58.1%. most common using canagliflozin, followed by empagliflozin and Dapagliflozin (100%, 77%, 48.3%, respectively). Overall, infection (32.6%) trigger for DKA, insulin non-compliance (13.7%). Infection only risk factor significant estimate two groups, being more hDKA (p-value 0.006, RR 2.53, 95% CI 1.07-5.98). Canagliflozin strongest association highest medical intensive unit (MICU) admission rates (66.6%). In SGLT2i, probably an increased developing EuDKA. differential role individual analogs less clear will need exploration extensive prospective studies.